Table 2

Patient distribution by biological line experience; n (%)

Index drugBionaive (%)Second line (%)Third line (%)Fourth line (%)
CZP169 (90.4)16 (8.6)2 (1.1)0 (0.0)
ETA1669 (94.5)88 (5.0)7 (0.4)1 (0.1)
ADA1322 (94.4)76 (5.4)2 (0.1)0 (0.0)
GLM586 (85.8)94 (13.8)1 (0.1)2 (0.3)
  • ADA, adalimumab; CZP, certolizumab pegol; ETA, etanercept; GLM, golimumab.